Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 2, 2016
NEWTON, Mass., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that company executives, including founder...
-
Oct 31, 2016
NEWTON, Mass., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report third quarter 2016...
-
Oct 11, 2016
NEWTON, Mass., Oct. 11, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Justin A. Renz, Executive Vice President,...
-
Oct 5, 2016- Single-Agent Selinexor Demonstrates Robust Clinical Benefit and Favorable Tolerability in Patients with Heavily Pre-treated Gynecologic Cancers -
NEWTON, Mass., Oct. 05, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that an oral presentation highlighting updated...
-
Sep 29, 2016- Nuclear Transport Machinery Identified as a Necessary and Universal Driver of KRAS-mutant Cell Survival -
NEWTON, Mass., Sept. 29, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that preclinical data describing XPO1...
-
Sep 28, 2016- XPO1 Inhibition Significantly Reduced Tumor Burden in Platinum Sensitive and Resistant Ovarian Cancer Models-
NEWTON, Mass., Sept. 28, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that preclinical and Phase 1 clinical data...
-
Sep 12, 2016
NEWTON, Mass., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the appointment of Humphrey A.R. Gardner MD,...
-
Sep 6, 2016- Selinexor Achieves Promising Response Rates in Patients with Multiple Myeloma, Including 20.8% in Quad-Refractory and 20.0% in Penta-Refractory Disease -
NEWTON, Mass., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported positive top-line results from its Phase 2b...
-
Aug 30, 2016
NEWTON, Mass., Aug. 30, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced it will provide an overview of top-line...
-
Aug 4, 2016Completed Enrollment in Phase 2b STORM Clinical Trial for Refractory Multiple Myeloma
NEWTON, Mass., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported financial results for the second quarter 2016...